The initiation of autoimmune diabetes

Current Opinion in Immunology

Volumn 11, Issue 6, 1999, Pages 663-669

  Green, E Allison ^a   Flavell, Richard A ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOIMMUNE DISEASE; DIABETES MELLITUS; HUMAN; IMMUNOLOGICAL TOLERANCE; INSULITIS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0032705672     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(99)00034-5     Document Type: Review

References (72)

1. Kurts C., Heath W., Kosaka H., Miller J., Carbone F. The peripheral deletion of autoreactive CD8+ T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). J Exp Med. 188:1998;415-420.
2. Kurts C., Miller J.F.A.P., Subramanian R.M., Carbone F.R., Heath W.R. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigen and those released during cellular destruction. J Exp Med. 188:1998;409-414.
3. Kurts C., Heath W.R., Carbone F.R., Allison J., Miller J.F.A.P., Kosaka H. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med. 184:1996;923-930.
4. Wong F., Karttunen J., Dumont C., Wen L., Visintin I., Pilip I., Shastri N., Pamer E., Janeway C.J. Identification of an MHC class I-restricted autoantigen in type I diabetes by screening an organ-specific cDNA library. Nat Med. 5:1999;1026-1031.
5. Yoon J., Yoon C., Lim H., Huang Q., Kang Y., Pyun K., Hirasawa K., Sherwin R., Jun H. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science. 284:1999;1183-1187.
6. Andreoletti L., Hober D., Nober-Vandenberghe C., Fajardy I., Belaich S., Lambert V., Vantyghem M., Lefebvre J., Wattre P. Coxsackie B virus infection and beta cell autoantibodies in newly diagnosed IDDM adult patients. Clin Diagn Virol. 9:1998;125-133.
7. Horwitz M.S., Bradley L.M., Habertson J., Krahl T., Lee J., Sarvetnick N. Diabetes induced by coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med. 4:1998;781-785.
8. Delovitch T.L., Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity. 7:1997;727-738.
9. O'Brien B.A., Harmon B.V., Cameron D.P., Allan D.J. Apoptosis is the mode of β-cell death responsible for the development of IDDM in the nonobese diabetic (NOD) mouse. Diabetes. 46:1997;750-757.
10. Green E., Eynon E., Flavell R. Local expression of TNFα in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. Immunity. 9:1998;733-743. This paper demonstrates that the expression of TNF-α in the islets of neonatal NOD mice accelerates diabetes progression. In part, this rapid progression to diabetes was related to the inflammatory environment recruiting DCs to neonatal islets and promoting DC activation in situ. These activated DCs bore islet-peptide complexes and were highly potent at stimulating anti-islet T cell responses.
11. Albert M.L., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 392:1998;86-89.
12. Scaglia L., Cahill C.J., Finewood D.T., Bonner-Weir S. Apoptosis particpates in the remodelling of the endocrine pancreas in the neonatal rat. Endocrinol. 138:1997;1736-1741.
13. Dahlén E., Dawe K., Ohlsson L., Hedlund G. Dendritic cells and macrophages are the first and major producers of TNFα in pancreatic islets in the nonobese diabetic mouse. J Immunol. 160:1998;3585-3593.
14. Jansen A., Voorbij H.A.M., Jeucken P.H.M., Bruining G.J., Hooijkaas H., Drexhage H.A. An immunohistochemical study on organized lymphoid cell infiltrates in fetal and neonatal pancreas. A comparison with similar infiltrates found in the pancreas of a diabetic infant. Autoimmunity. 15:1993;31-38.
15. Rosmalen J.G.M., Leenen P.J.M., Katz J.D., Voerman J.S.A., Drexhage H.A. Dendritic cells in the autoimmune insulitis in NOD mouse models of diabetes. Adv Exp Med Biol. 417:1997;291-294.
16. Voorbij H.A.M., Jeucken P.H.M., Kabel P.J., De Haan M., Drexhage H.A. Dendritic cells and scavenger macrophages in pancreatic islets of prediabetic BB rats. Diabetes. 38:1989;1623-1629.
17. Rovere P., Vallinoto C., Bondanza A., Crosti M.C., Rescigno M., Ricciardi-Castagnoli P., Rugarli C., Manfredi A.A. Cutting edge: bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol. 161:1998;4467-4471.
18. Rovere P., Sabbadini M., Vallinoto C., Fascio U., Zimmermann V., Bondanza A., Ricciardi-Castagnoli P., Manfredi A. Delayed clearance of apoptotic lymphoma cells allows cross-presentation of intracellular antigens by mature dendritic cells. J Leukoc Biol. 66:1999;345-349.
19. Ronchetti A., Iezzi G., Crosti M., Garancini M., Protti M., Bellone M. Role of antigen-presenting cells in cross-priming of cytotoxic T lymphocytes by apoptotic cells. J Leukoc Biol. 66:1999;247-251.
20. Carroll M. The lupus paradox. Nat Genet. 19:1998;3-4.
21. Mevorach D., Zhou J., Song X., Elkon K. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med. 188:1998;387-392.
22. Casteels K., Gysemans C., Waer M., Bouillon R., Laureys J., Depovere J., Mathieu C. Sex difference in resisitance to dexamethasone-induced apoptosis in NOD mice. Diabetes. 47:1998;1033-1037.
23. Penha-Gonçalves C., Leijon K., Persson L., Holmgren D. Type 1 diabetes and the control of dexamethazone-induced apoptosis in mice maps to the same region on chromosome 6. Genomics. 28:1995;398-404.
24. Hernandez-Hoyos G., Joseph S., Miller N., Butcher G., The lymphopenia mutation of the B.B. rat causes inappropriate apoptosis of mature thymocytes. Eur J Immunol. 29:1999;1832-1841.
25. Martins T., Aguas A. NOD mice are resistant to depletion of thymic cells caused by acute stress or infection. Autoimmunity. 29:1999;273-280.
26. Akashi T., Nagafuchi S., Anzai K., Kondo S., Kitamura D., Wakana S., Ono J., Kikuchi M., Niho Y., Watanabe T. Direct evidence for the contribution of B cells to the progression of insulitis and development of diabetes in non-obese diabetic mice. Int Immunol. 9:1997;1159-1164.
27. Noorchashm H., Noorchashm N., Kern J., Rostami S.Y., Barker C.F., Naji A. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes. 46:1997;941-946.
28. Serreze D.V., Chapman H.D., Varnum D.S., Hanson M.S., Reifsnyder P.C., Richard S.D., Fleming S.A., Leiter E.H., Shultz L.D. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new 'speed congenic' stock of NOD.Igu null mice. J Exp Med. 184:1996;2049-2053.
29. Serreze D.V., Fleming S.A., Chapman H.D., Richard S.D., Leiter E.H., Tisch R.M. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol. 161:1998;3912-3918.
30. King C., Davies J., Mueller R., Lee M.-S., Krahl T., Yeung B., O'Connor E., Sarvetnick N. TGF-β1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype. Immunity. 8:1998;601-613.
31. Delon J., Bercovici N., Raposo G., Liblau R., Trautmann A. Antigen-dependent and independent Ca2+ responses triggered in T cells by dendritic cells compared with B cells. J Exp Med. 188:1998;1473-1484.
32. Ingulli E., Mondino A., Khoruts A., Jenkins M.K. In vivo detection of dendritic cell antigen presentation to CD4+ T cells. J Exp Med. 185:1997;2133-2141.
33. + T cell responses towards the β-cells and subsequently induce diabetes.
34. Matsue H., Edelbaum D., Hartmann A., Morita A., Bergstresser P., Yagita H., Okumura K., Takashima A. Dendritic cells undergo rapid apoptosis in vitro during antigen-specific interaction with CD4+ T cells. J Immunol. 162:1999;5287-5298.
35. Tarkowski E., Blennow K., Wallin A., Tarkowski A. Intracerebral production of tumor necrosis factor alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol. 19:1999;223-230.
36. Jansen A., van Hagen M., Drexhage H.A. Defective maturation and function of antigen-presenting cells in type 1 diabetes. The Lancet. 345:1995;491-492.
37. Takahashi K., Honeyman M.C., Harrison L.C. Impaired yield, phenotype, and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes. J Immunol. 161:1998;2629-2635.
38. Vremec D., Shortman K. Dendritic cell subtypes in mouse lymphoid organs: cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen, and lymph nodes. J Immunol. 159:1997;565-573.
39. Winzler C., Rovere P., Rescigno M., Granucci F., Penna G., Adorini L., Zimmerman V.S., Davoust J., Ricciardi-Castagnoli P. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med. 185:1997;317-328.
40. - DCs stimulate Th2 responses.
41. Ohteki T., Fukao T., Suzue K., Maki C., Ito M., Nakamura M., Koyasu S. Interleukin 12-dependent interferon γ production by CD8α+ lymphoid denritic cells. J Exp Med. 189:1999;1981-1986.
42. Smith A.L., de St Groth B.F. Antigen-pulsed CD8α+ dendritic cells generate an immune response after subcutaneous injection without homing to the draining lymph node. J Exp Med. 189:1999;593-598.
43. Rougier N., Schmidtt D., Vincent C. IL-4 addition during differentiation of CD34 progenitors delays maturation of dendritic cells while promoting their survival. Eur J Cell Biol. 75:1998;287-293.
44. Cella M., Engering A., Pinet V., Pieters J., Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature. 388:1997;782-787.
45. Munn D., Shafizadeh E., Attwood J., Bondarev I., Pashine A., Mellor A. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 189:1999;1363-1372. This paper demonstrates that stimulation of macrophages results in the expression of the tryptophan-degrading enzyme, IDO, and that production of this enzyme is critical for promoting macrophage-mediated inhibition of T cell responses.
46. Munn D., Zhou M., Attwood J., Bondarev I., Conway S., Marshall B., Brown C., Mellor A. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 281:1998;1191-1193.
47. Thompson C.B., Allison J.P. The emerging role of CTLA-4 as an immune attenuator. Immunity. 7:1997;445-450.
48. Kwon B., Youn B.-S., Kwon B. Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes. Curr Opin Immunol. 11:1999;340-345.
49. Foy T.M., Shepherd D.M., Durie F.H., Aruffo A., Ledbetter J.A., Noelle R.J. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J Exp Med. 178:1993;1567-1575.
50. Grewal I.S., Xu J., Flavell R.A. Impairment of antigen-specific T cell priming in mice lacking CD40 ligand. Nature. 378:1995;617-620.
51. Stout R.D., Suttles J., Xu J., Grewal I.S., Flavell R.A. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J Immunol. 156:1996;8-11.
52. Xu J., Foy T.M., Laman J.D., Elliott E.A., Dunn J.J., Waldschmidt T.J., Elsemore J., Noelle R.J., Flavell R.A. Mice deficient for the CD40 ligand. Immunity. 1:1994;423-431.
53. Grewal I.S., Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 16:1998;111-135.
54. Balasa B., Krahl T., Patstone G., Lee J., Tisch R., McDevitt H.O., Sarvetnick N. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol. 159:1997;4620-4627.
55. Grewal I.S., Foellmer H.G., Grewal K.D., Xu J., Hardardottir F., Baron J.L., Janeway C.A.J., Flavell R.A. Requirement for CD40 ligand in co-stimulation induction, and experimental allergic encephalomyelitis. Science. 273:1996;1864-1867.
56. Mach F., Shonbeck U., Sukhova G.K., Atkinson E., Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature. 394:1998;200-203.
57. + T cell help.
58. ••].
59. ••].
60. Gordon E., Markees T., Phillips N., Noelle R., Shultz L., Mordes J., Rossini A., Greiner D. Prolonged survival of rat islet and skin xenografts in mice treated with donor splenocytes and anti-CD154 monoclonal antibody. Diabetes. 47:1998;1199-1206.
61. Borrow P., Tough D.F., Eto D., Tishon A., Grewal I.S., Sprent J., Flavell R.A., Oldstone B.A. CD40 ligand-mediated interactions are involved in the generation of memory CD8(+) cytotoxic T lymphocytes (CTL) but are not required for the maintenance of CTL memory following virus infection. J Virol. 72:1998;7440-7449.
62. + T cell responses in CD40-deficient mice were abrogated by injection of an anti-TRANCE-receptor antibody.
63. Green E.A., Flavell R.A. TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation. J Exp Med. 189:1999;1017-1020.
64. + T cells.
65. Gilfillan M., Noel P., Podack E., Reiner S., Thompson C. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol. 160:1998;2180-2187.
66. Takahashi C., Mittler R.S., Vellas A.T. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol. 162:1999;5037-5040.
67. Shuford W., Klussman K., Tritchler D., Loo D., Chalupny J., Siadak A., Brown T., Emswiler J., Raecho H., Larsen C.et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med. 186:1997;47-55.
68. DeBenedette M., Shahinian A., Mak T., Watts T. Costimulation of CD28- T lymphocytes by 4-1BB ligand. J Immunol. 158:1997;551-559.
69. Guinn B.A., DeBenedette M., Watts T., Berinstein N. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol. 162:1999;5003-5010.
70. Weinberg A., Wegmann K., Funatake C., Whitman R. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalitis. J Immunol. 162:1999;1818-1826.
71. Weinberg A.D. Antibodies to OX-40 (CD134) can identify and eliminate autoreactive T cells: implications for human autoimmune disease. Mol Med Today. 4:1998;76-83.
72. Higgins L., McDonald S., Whittle N., Crockett N., Shields J., MacDonald T. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol. 162:1999;486-493.